Please join us for an Open Scientific Discussion (OSD) hosted by the AAPS Biomarkers and Precision Medicine (BPM) Community on January 15^th, 2026, 12 pm – 1 pm ET on the following topic:

 
Featured 2025 PharmSci 360 Biomarker Posters:  A Collection for Community Discussion

This OSD will showcase the following posters that caught our Biomarker Community's interest.

• Comparison of Exosome Isolation Methods for the Analysis of a Disease Biomarker in Serum and Urine by PCR Methodologies
• Comparison of Novel Whole Blood Preservation Methods as Alternative to Cryopreserved PBMC for Immunophenotyping in Multicenter Clinical Trials

Presenters:

• Jean Paul Ouedraogo (Charles River Laboratories)
• Thomas (TJ) Beadnell (Eurofins)

 
Organizers:  Carmen Fernández-Metzler (PharmaCadence) and Karen Quadrini (Prothena Biosciences)

 
We start at 12:00 EST sharp. To avoid interruptions, please dial in before noon and mute yourself until Q&A starts.

(Please remain on mute unless asking questions)

 
When: Thursday, Jan 15, 2026, 12 pm – 1 pm EST

Where: Please join from your computer, tablet or smartphone.

Microsoft Teams Need help?

Join the meeting now

Meeting ID: 244 985 260 423 28

Passcode: Mk6GJ95g

Please feel free to share with colleagues who may be interested in this topic.

The AAPS Journal just shared this #editorial from the AAPS Biomarker & Precision Medicine Community on the 2025 FDA BMVB Guidance with authors spanning 19 organizations.

AAPS Communities unite members with a common interest in a specific topic in a web-based, always-available, virtual environment. Join us in giving a round of applause to these Community leaders. 👏 👏

Please join us for an Open Scientific Discussion (OSD) hosted by the Biomarkers and Precision Medicine (BPM) Community on July 9, from 1-2 PM ET on the following topic:

Multi-Parametric Biomarker Signatures

·         How do we go from identifying a potential biomarker with omics tools to an assay that is used in clinical trials?

·         Examples of biomarker panel assay use:  Renal safety biomarkers, Alzheimer’s disease, pharmacodynamic signatures

·         Challenges in establishing and translating multi-parameter biomarker assays to the clinic

Discussion Leaders:

Tom Lanz (Pfizer)

Tim West (C2N Diagnostics)

Chris Whelan (formerly Johnson & Johnson)

Organized by:  

Joel Matthews (Ionis Pharmaceuticals)

Jurre Kamphorst (AstraZeneca)

Carmen Fernández-Metzler (PharmaCadence Analytical Services)

Karen Quadrini (Prothena Biosciences)

We start at 1:00 ET sharp. To avoid interruptions, please dial in before noon and mute yourself until Q&A starts.

(Please remain on mute unless asking questions)

When: Wednesday July 9, 2025, 1 pm – 2 pm ET

Where: Please join from your computer, tablet or smartphone.

Microsoft Teams Need help?

Join the meeting now

Meeting ID: 279 600 469 385 3

Passcode: jg3oC6Uj

Please feel free to share with colleagues who may be interested in this topic. Thank you!

The AAPS BPM Community Leadership Team

📅 Date: Monday, June 16, 2025

🕛 Time: 12:00 PM – 1:00 PM Eastern Time

📍 Location: Virtual Seminar @ https://global.gotomeeting.com/join/271724949

🧪 OSD Overview

Join us for an engaging 1-hour discussion featuring:

Dr. Gabriela Hernandez Hoyos (BMS) and Dr. Ilayaraja Muthuramu (J&J)
Experts in genomic risk analysis and safety assessments of CAR T platforms

They will explore:

●        Genomic risks in lentiviral vs. gene-edited CAR T products

●        Key molecular and functional assays used in risk assessment

●        Preclinical safety challenges in autologous vs. allogeneic approaches

●        Insights from published case studies and FDA-approved testing strategies

🧠 Who Should Attend?

Scientists, researchers, and professionals working in:
- Gene and cell therapy
- Regulatory science
- Oncology R&D
- Translational medicine

🔗 Why Attend?

- Hear from leaders in the field
- Participate in an open discussion on safety assessment strategies
- Gain insights into regulatory and translational approaches for CAR T therapies